BioSpace News Archive

Siolta Therapeutics, a clinical-stage biotech company, announced it has raised $30M in a series B investment round to support the clinical development of its lead product, STMC-103H.

Dallas-based UT Southwestern Medical Center’s Simmons Cancer Center, one of the elite centers in the country for patient care, research and education joins Caris’ best-in-class collaborative research network focused on expanding the application of precision medicine in oncology

Renalytix AI, Inc., an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announced that it has received a California Clinical Laboratory License from the California Department of Health for its clinical laboratory in Salt Lake City, Utah.

Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced that the U.S. Food and Drug Administration (FDA) has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to MDR-101, Medeor’s therapy designed to enable immune tolerance in kidney transplant patients, thereby eliminating the need for

FDA set a target action date of March 27, 2021 Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma PRINCETON, N.J., & CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc . (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review their Biologics License Application (BLA) for idecabtagene vicle

BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases and cancers with clear genetic drivers, today announced that it will host its first R&D Day on Tuesday, September 29, at 8:30 am E.T. The virtual event will feature presentations from BridgeBio founder and CEO, Neil Kumar, Ph.D., senior scientists and physicians leading BridgeBio’s drug discovery and development programs, and

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the completion of enrollment of its Phase 2a study of FX-322 for sensorineural hearing loss (SNHL). The company anticipates obtaining full results for the study, in which 95 patients were enrolled, i

Emmetrope Ophthalmics LLC (“Emmecell”), a clinical-stage biotechnology company pioneering the discovery and development of cell-based therapies for the treatment of eye diseases, today announced that the

Avricore Health Inc. (TSXV: AVCR, OTC: AVCRF) (“Avricore” or the “Company”) is pleased to announce the signing of a Letter of Intent (LOI) with a prominent, publicly traded healthcare technology company and drug maker which serves as the foundation to integrate a propriety point-of-care blood chemistry analyzer into Avricore’s HealthTab™ real-time data reporting system.

Clinical Genomics (“CG” or the “Company”), a provider of cancer diagnostic solutions, including liquid biopsy tests for recurrence monitoring of colorectal cancer (CRC), today announced the publication of the NOVA clinical trial in the prestigious Cancer Epidemiology, Biomarkers & Prevention Journal. This U.S. population study further reinforces the performance of COLVERA ® , the breakthrough blood test for the clinical presence of CRC